Bispecific T-cell engager antibody (CD3×CD19) that redirects T cells to lyse CD19-positive B-ALL cells.
Recombinant bispecific antibody (CD3×CD19) that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to form an immune synapse and activate T-cell cytotoxicity, leading to perforin/granzyme-mediated lysis of CD19-positive B-ALL cells.
YES
DIRECT
Blinatumomab bridges CD3 on T cells to CD19 on target cells, activating T cells to kill CD19+ cells via perforin/granzyme-mediated cytolysis.
Bispecific T-cell engager antibody (CD3×CD19) that redirects T cells to lyse CD19-positive B-ALL cells.
Recombinant bispecific antibody (CD3×CD19) that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to form an immune synapse and activate T-cell cytotoxicity, leading to perforin/granzyme-mediated lysis of CD19-positive B-ALL cells.
NO
INDIRECT
Blinatumomab binds CD3 on T cells to activate and redirect them to kill CD19-positive B cells via perforin/granzyme; CD3+ cells are effectors, not targets.
Humanized, Fc‑engineered anti‑CD19 IgG1 monoclonal antibody that targets CD19 on B cells and mediates tumor killing via ADCC, ADCP, and direct pro‑apoptotic signaling; used for R/R DLBCL in combination with lenalidomide.
Fc‑engineered humanized anti‑CD19 IgG1 monoclonal antibody that binds CD19 on B cells and depletes CD19+ malignant B cells by enhancing FcγR engagement to drive ADCC and ADCP, and by inducing direct pro‑apoptotic signaling.
YES
DIRECT
The anti-CD19 IgG1 binds CD19 on B cells and kills via Fc gamma receptor–mediated ADCC (e.g., NK cells) and ADCP (macrophages), and can also trigger direct pro-apoptotic signaling in CD19+ cells.
Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and induction of apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre‑B and mature B lymphocytes, triggering complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and direct apoptosis to deplete CD20-positive B cells.
YES
DIRECT
Rituximab binds CD20 on B cells and kills via complement-dependent cytotoxicity, Fc-mediated ADCC/ADCP by immune effector cells, and can directly induce apoptosis of CD20+ cells.
CD20×CD3 bispecific T-cell–engaging antibody that redirects T cells to kill malignant CD20-positive B cells.
CD20×CD3 bispecific antibody that simultaneously binds CD3 on T cells and CD20 on B cells, forming an immunologic synapse that activates and redirects T cells to kill CD20-positive B cells via CTL-mediated cytotoxicity.
YES
DIRECT
Glofitamab links CD3 on T cells to CD20 on target cells, forming an immunologic synapse that activates T cells to kill CD20+ cells via perforin/granzyme-mediated cytolysis and apoptosis.